Every 10-Q that Mustang Bio, Inc. (MBIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MBIO filings page.
Mustang Bio, Inc. is a clinical-stage oncology company with no approved products and continued losses as it develops CAR T and oncolytic virus therapies for difficult-to-treat brain cancers. For the quarter ended June 30, 2026 it reported a net loss of $1.072 million and operating expenses of $1.17 million, up 32% year over year, driven by higher research and personnel costs. For the first six months of 2026, net loss was $2.0 million.
Cash and cash equivalents were $15.2 million and total assets $15.6 million at June 30, 2026, with stockholders’ equity of $7.5 million and an accumulated deficit of $400.7 million. Management expects this cash to fund operations for at least twelve months but continues to forecast substantial future losses and may need significant additional capital under constrained “baby shelf” limits. The company relies on a $40.0 million Form S-3 shelf (about $34.2 million remaining) and an at-the-market program, though no shares were sold in the first half of 2026. Mustang received FDA Orphan Drug Designations for MB-108 and MB-101 and is working with academic partners toward a potential fourth-quarter 2026 investigator-sponsored trial of combination therapy MB-109 in recurrent glioblastoma and high-grade astrocytoma. In April 2026 Nasdaq notified Mustang that its share price no longer met the $1.00 minimum bid requirement; Mustang has until October 12, 2026 to regain compliance or risk delisting.
Mustang Bio reports a Q1 2026 net loss of $0.96 million, compared with $0.15 million a year earlier, as it continues developing cell therapies for difficult-to-treat cancers.
At March 31 2026, Mustang held $16.3 million in cash and cash equivalents, total assets of $16.6 million, total liabilities of $8.0 million and stockholders’ equity of $8.6 million. The accumulated deficit reached $399.6 million, but management believes existing cash will fund operations for at least 12 months from the financial statement issuance date.
Operating expenses were modest, with research and development of $0.18 million and general and administrative costs of $0.88 million. The company remains pre‑revenue and relies on equity financing, including a 2024 shelf registration with about $34.2 million capacity remaining under Form S‑3 but constrained by “baby shelf” limits. After quarter‑end, Nasdaq notified Mustang that its share price fell below the $1.00 minimum bid requirement, starting a grace period to regain compliance.
Mustang Bio (MBIO) reported Q3 2025 results with a net loss of $0.468 million, improved from a $1.410 million loss a year ago, as lower operating costs and one-time credits reduced expenses. Cash and cash equivalents were $18.984 million at September 30, 2025, up from $6.839 million at year-end, and total stockholders’ equity was $9.771 million.
The company completed a 1-for-50 reverse split in January and raised capital through a February 2025 equity offering with net proceeds of approximately $6.8 million, followed by July warrant exercises adding about $7.1 million; an at-the-market program contributed $0.6 million year-to-date. Management disclosed “substantial doubt” about the ability to continue as a going concern without additional financing.
Pipeline updates include FDA Orphan Drug Designations for MB-108 and MB-101 and exploration of an investigator-sponsored MB-109 study at City of Hope as early as the second quarter of 2026. In September 2025, Fred Hutch provided notice of intent to terminate the CD20 license, subject to a 90‑day cure period, and the parties plan to negotiate terms.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on CAR T and oncolytic virus therapies. For the quarter ended June 30, 2025, the company reported cash and cash equivalents of $12.7 million and total assets of $13.0 million, funded largely by equity financings. Total liabilities were $10.2 million and stockholders' equity improved to $2.9 million from a deficit of $3.9 million at year-end 2024.
Operating results show a substantially reduced loss compared with prior-year periods: net loss was $762,000 for the quarter and $915,000 for the six months ended June 30, 2025, versus significantly larger losses in 2024. The company generated approximately $6.8 million net proceeds from a February 2025 equity offering and ~$0.6 million from ATM sales during the period; subsequent July 2025 warrant exercises raised ~$7.1 million.
Management discloses substantial doubt about the company's ability to continue as a going concern and states additional financing will be required to advance clinical programs.